Psychedelic Therapeutics Market Size, Share & Trends Analysis Report, by Origin of Substance (Natural and Synthetic), Type of Psychedelic Substance (Gamma-hydroxybutyrate, Ketamine, MDMA, and Psilocybin), Target Disease Indications (Depression and Anxiety Disorders, Pain Disorders, Sleep Related Disorders and Trauma), Route of Administration, By Region, Forecasts, 2025-2034
Segmentation Of Psychedelic Therapeutics Market
Psychedelic Therapeutics Market- By Origin of Substance
- Natural
- Synthetic
Psychedelic Therapeutics Market- By Type of Psychedelic Substance
- Gamma-hydroxybutyrate
- Ketamine
- MDMA
- Psilocybin
Psychedelic Therapeutics Market- By Target Disease Indications
- Depression and Anxiety Disorders
- Pain Disorders
- Sleep-Related Disorders
- Trauma
Psychedelic Therapeutics Market- By Route of Administration
- Oral
- Intravenous
- Intranasal
- Sublingual
Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region
Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- U.K.
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- U.S.
- Canada
Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psychedelic Therapeutics Market Snapshot
Chapter 4. Global Psychedelic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Origin of Substance Estimates & Trend Analysis
5.1. by Origin of Substance & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Origin of Substance:
5.2.1. Natural
5.2.2. Synthetic
Chapter 6. Market Segmentation 2: by Type of Psychedelic Substance Estimates & Trend Analysis
6.1. by Type of Psychedelic Substance & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Psychedelic Substance:
6.2.1. Gamma-hydroxybutyrate
6.2.2. Ketamine
6.2.3. MDMA
6.2.4. Psilocybin
Chapter 7. Market Segmentation 3: by Target Disease Indications Estimates & Trend Analysis
7.1. by Target Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Disease Indications:
7.2.1. Depression and Anxiety Disorders
7.2.2. Pain Disorders
7.2.3. Sleep Related Disorders
7.2.4. Trauma
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration& Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Intranasal
8.2.4. Sublingual
Chapter 9. Psychedelic Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.1.2. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.1.3. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.1.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.1.5. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.2.2. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.2.3. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.2.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.3.2. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.3.3. Asia-Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.3.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.4.2. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.4.3. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034 North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.4.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.5.2. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.5.3. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.5.4. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Celon Pharma S.A.
9.2.2. MAPS Public Benefit
9.2.3. MindMed
9.2.4. Janssen Pharmaceuticals
9.2.5. iX Biopharma Ltd
9.2.6. Jazz Pharmaceutical
9.2.7. Avadel
9.2.8. Pharmaceuticals plc
9.2.9. NeuroRx, Inc.
9.2.10. Douglas Pharmaceuticals Limited
9.2.11. The Emmes
9.2.12. Company, LLC
9.2.13. CaaMTech
9.2.14. COMPASS Pathways plc
9.2.15. Eleusis Benefit Corporation
9.2.16. AWAKN Life Sciences Inc
9.2.17. Psilera Bioscience
9.2.18. Braxia Scientific Corp.
9.2.19. Mindset Pharma
9.2.20. BetterLife Pharma
9.2.21. Cybin
9.2.22. CB Therapeutics
9.2.23. Numinus Wellness
9.2.24. Mydecine Innovations Group
9.2.25. Optimi Health
9.2.26. PharmaTher
9.2.27. Field Trip Health
9.2.28. ATAI Life Sciences
9.2.29. GH Research
9.2.30. Seelos Therapeutics
9.2.31. Small Pharma
9.2.32. Bright Minds Biosciences
9.2.33. Incannex Health
9.2.34. PsyBio Therapeutics
9.2.35. Universal Ibogaine
9.2.36. Levitee Labs
9.2.37. Mind Cure Health
9.2.38. Novamind
9.2.39. Clearmind Medicine
9.2.40. MYND Life Science
9.2.41. Wesana Health
9.2.42. Psyched Wellness
9.2.43. HAVN Life Sciences
9.2.44. Tryp Therapeutics
9.2.45. Psyence Group
9.2.46. Silo Pharma
9.2.47. Core One Labs
9.2.48. M2Bio Sciences
9.2.49. Neonmind Biosciences
9.2.50. Delic Corp
9.2.51. Nova Mentis Life Science
9.2.52. Beckley Psytech
9.2.53. Delix Therapeutics
9.2.54. Diamond Therapeutics
9.2.55. Tactogen
9.2.56. Psygen Labs Inc.
9.2.57. Bexson Biomedical
9.2.58. Eleusis Biotech
9.2.59. Psilera Biosceince
9.2.60. Octarine Bio
9.2.61. Heading Health
9.2.62. MAPS Public Benefit Corporation (PBC)
9.2.63. Aphrodite Health
9.2.64. Terran Biosciences
9.2.65. Mycrodose Therapeutics
9.2.66. Reset Pharma
9.2.67. Clerkenwell Health
9.2.68. Alvarius Pharmaceuticals
9.2.69. Ceruvia Lifesciences
9.2.70. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034
Psychedelic Therapeutics Market is expected to grow at a 15.6% CAGR during the forecast period for 2025-2034
Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx,
Type of Psychedelic Substance, Origin of Psychedelic Substance and Target Therapeutic Area are the key segments of the Psychedelic Therapeutics Market
North American region is leading the Psychedelic Therapeutics Market.